TMDXNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
TransMedics Group, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$71.60+0.82 (+1.16%)
Close on Oct 19, 2026
- Market cap
- $2.91B
- P/E (TTM)
- 18.6
- Dividend yield
- 0.00%
TransMedics Group, Inc. cash flow statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 58.7%
- Operating margin
- 12.2%
- Net margin
- 22.7%
- Return on equity, FY2025
- 54.2%
Financial strength
- Current ratio
- 6.62
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 480.9%
Valuation
- P/E ratio
- 18.6
- Price to sales
- 4.36
- Price to book
- 5.63
- Dividend yield
- 0.00%